GT Biopharma (GTBP) vs Medicus Pharma (MDCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GT Biopharma (GTBP) has outperformed Medicus Pharma (MDCX) over the past year, gaining 451.9% versus a loss of 95.9%. GT Biopharma is the larger company by market cap ($11.3 million vs $138,368), about 81.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GTBP | MDCX |
|---|---|---|
| Share price | $6.24 | $0.0923 |
| Market cap | $11.25M | $138.37K |
| 1-day change | +4.79% | -9.42% |
| YTD return | +659.24% | -93.34% |
| 1-year return | +451.85% | -95.86% |
| 5-year return | -96.72% | — |
| EPS (TTM) | $-147.50 | $-119.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.75 | $139.00 |
| 52-week low | $4.91 | $0.084 |
| Distance from 52-week high | -78.31% | -99.93% |
| Analyst consensus | none | none |
| Avg. price target upside | +1102.89% | +4775.41% |
| Average volume | 55.52K | 92.96K |
| Shares outstanding | 1.80M | 1.50M |
| Employees | 1 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GT Biopharma is about 81.3 times larger than Medicus Pharma by market value ($11.25M vs $138.37K).
- GTBP has outperformed MDCX by 547.7 percentage points over the past year.
About GT Biopharma
GTBP stock →GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
GTBP vs MDCX FAQ
Which is bigger, GT Biopharma or Medicus Pharma?
GT Biopharma (GTBP) is larger, with a market capitalization of $11.25M compared with $138.37K for Medicus Pharma (MDCX).
Which stock has performed better over the past year, GTBP or MDCX?
GTBP returned +451.85% over the past 12 months, compared with -95.86% for MDCX (price return, excluding dividends). Past performance does not predict future results.
Are GT Biopharma and Medicus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.